Main text
Whereas genetic 1-6 epidemiological 7-11 and pathophysiological [12] [13] [14] studies implicate autoimmunity in response to flu infection in type 1 narcolepsy (T1N), a disease caused by hypocretin (HCRT) neuronal loss [15] [16] [17] the identity of the autoantigen is unknown.
Potential autoantigens explored have included HCRT sequences [18] [19] [20] [21] , HCRT receptor 2 sequences 22 and the protein TRIB2 23 but these results have been either withdrawn 24 or found not to be conclusive or replicated [25] [26] [27] . Similarly, staining of hypothalamic slices with T1N sera has been found negative 28 .
Extending on prior work [1] [2] [3] [4] [5] [6] a large recent GWAS analysis in over 4,500 patients across multiple ethnic groups confirmed primordial importance of the Human Leukocyte Antigen (HLA) DQ0602 heterodimer in disease predisposition, with important secondary associations in T cell receptor loci and and other loci suggesting importance of DQ0602 presentation of antigens to CD4 + by Antigen Presenting Cells (APC) and likely subsequent CD8 + destruction of hypocretin cells 29 . Hypocretin cell killing through CD4 + and CD8 + mediation has also been shown to cause narcolepsy in an animal model 30 .
Much has recently been learned regarding what may trigger T1N autoimmunity. Onset of T1N in children, which often can be timed to the week, is seasonal and peaks in spring and summer 10 . Onset has also been associated with Streptococcus Pyogenes infections 9, 31 and Influenza-A 10 , suggesting trigger may be a winter infection, followed by a variable delay peaking at 5 months where complete hypocretin cell loss has occurred and symptoms appear. Most strikingly prevalence of T1N increased several folds in China and Taiwan with a similar delay following the 2009-2010 "swine" flu H1N1 influenza pandemic (pH1N1) 10, 32, 33 , although this is less variable in other countries 11, 34 .
Similarly, cases of T1N have been triggered by Pandemrix ® in Europe with relative risk increasing 5 to 14-fold in children and adolescents and 2 to 7-fold in adults after vaccination 33 . As Pandemrix ® is an adjuvanted vaccine containing the artificially produced reassortant strain X-179A, a mix of PR8, an old H1N1 strain derived from pre-2009 seasonal H1N1 and containing key H1N1 2009 surface proteins (Hemagglutinin-HA and Neuraminidase-NA) 35 , it is likely flu protein are critically involved. The fact the HLA and TCR genetic associations are universal 6, [36] [37] [38] [39] [40] is also consistent with a flu trigger, as these infections are worldwide 41 . The situation is nonetheless likely complex as even with Pandemrix ® vaccination, only 1 for 16,000 of vaccinated children ever developed T1N, suggesting the need for additional factors. Similarly, as mentioned above, effects of the H1N12009 pandemic and vaccination on T1N have been variable across countries (and vaccines), suggesting the need for additional factors.
Results

DQ0602 restricted epitopes of H1N1 flu responses in T1N versus controls suggest a role for pHA273-287 and NP17-31
Complementing our previously published data 18, 24 , we screened overlapping 15-mers for DQ0602 binding for key proteins contained in X-179A and 2009H1N1 wild type, HA, NA, Influenza RNA-dependent RNA polymerase subunit 1 (PB1) and nucleoprotein (NP) (Supplementary Table 1 ). HA and NA were selected as these are key surface proteins enriched by design in flu vaccines such as Pandemrix ® (to facilitate B cell responses) 35, 42 . PB1 was selected because it is of H1N12009 origin in Pandemrix ® and thus is also shared by the wild type H1N12009 virus and Pandemrix ® , two known triggers of T1N 35, 42 . We finally added NP as it is the most abundant protein in flu and is also present in large amount in Pandemrix® as enrichment process for surface proteins is not absolute in this vaccine (and many others, although some subunit specific vaccine were available, such as Focetria ® for pH1N1) 35 . NP of Pandemrix ® is of backbone PR8 origin 35, 42 . Screening was primarily done using A/reassortant/NYMC X-179A (California/07/2009 x NYMC X-157, reference ADE2909) sequences complemented by wild type pH1N1 sequence (A/California/07/2009, reference AFM728) when polymorphism was evident, or sequences are of distinct origin (i.e. NP). Screening for these proteins identified large number of binders (Supplementary Table 1 ) using the biotin-conjugated EBV490-503 epitope (Bio-EBV, Bio-GGGRALLARSHVERTTDE), a known binder 18, 43 . Peptides that outcompeted >75% of the reference peptide signal were considered binders, and these were selected for tetramer screening 18 24 .
To assess for the presence of CD4 + T cell reactive to these epitopes, likely 9 mer-MHC class II binding repertoires were determined for all binders using three Immune Epitope Database prediction algorithms (SMM_align, NN_align, and consensus) and similarity scores. Peptides (15-mers) surrounding the cores and displacing most of the bio-EBV peptide in competition assays were used to construct tetramers by peptide exchange using biotinylated DQ0602 (Bio-DQ0602) cleaved with thrombin as described in the methods section. These tetramers were then used to FACS stain 10-day expanded peripheral blood mononuclear cells (PBMCs) cultures of 6 cases and 4 DQ0602 controls stimulated with Pandemrix® (100ng/ml) or the corresponding single peptide (6.26 nM) (see methods and staining results in Supplementary Figure 1A) . The control and narcoleptic subjects were all known past Pandemrix® vaccinees except for one case who developed T1N independent of vaccination 6 months prior to blood sampling (recent onset case). In contrast, lower reactivity with PB1 versus HA, NP and NA was found, likely the consequence of the lower concentration of PB1 in the Pandemrix ® vaccine (and all vaccines) in comparison to these other proteins 35 .
X179A derived tetramers with the most staining included pHA273-287, pNA217-231, NP17-31, NP261-275 ( Figure 1D ) suggesting these epitopes are immunodominant ( Figure 1A , NP epitopes from pH1N1 instead of PR8 indicated by stars). Other immunodominant peptides include pHA209-223, pHA321-335, pHA437-451, pNA145-59, pNA1217-231, NP261-275s (shared epitope between pH1N1 and PR8), NP437-451-pH1N1*, and NP365-379. HA1273-287 is notable as it was previously reported to have homology with prepro-hypocretin sequences HCRT54-66 and HCRT86-97 and suggested be involved in a possible pathogenic mimicry using Enzyme-Linked ImmunoSpot (ELISpot) results, a publication that was retracted based on flawed ELISpot results (DQ0602 binding results were all verified) 18, 24 (note that none of the authors of this publication were not involved in the Figure 2D) . Findings with pNA217-231, NP261-275 and NP17-31-pH1N1, the homologous sequence of PR8 NP17-31 in pH1N1 (2 amino acid difference in the core, see Supplementary Table 2) showed no differences overall and in subgroups ( Supplementary Figure 2A-C ). This further demonstrate that increased reactivity in T1N versus controls is not broadly shared across all H1N1 epitopes, confirming screening results presented in Figure 1C .
Broad CD4 + T cell autoreactivity to amidated HCRT54-66-NH2 and HCRT86-97-NH2 fragments when presented by DQ0602
We next tested whether T1N was associated with autoreactivity involving two proteins known to be primarily colocalized with hypocretin, hypocretin itself and RFX4, a transcription factor primarily expressed in testis and also exceptionally abundant in hypocretin cells. Hypocretin and RFX4 binders were tested in the 10 subjects mentioned above, with results suggesting almost no or little cross reactivity, consistent with T cell tolerance toward autoantigen peptide sequences ( Figure 1B) . Autoreactivity was significantly lower than for all viral proteins ( Figure 1C ).
Because the pre-prohypocretin peptide is cleaved and post-translationally modified in the region where homologous sequences HCRT54-66 and HCRT86-97 are located (resulting in secreted hypocretin-1 and -2), most notably C-amidated, a transformation necessary to its biological activity, we also tested HCRT54-66-NH2 and HCRT86-97-NH2, modified peptides we have previously shown also bind DQ0602 with similar or higher affinity 18 . To our surprise, T cell reactivity to these fragments was high in both DQ0602 controls and T1N subjects ( Figure 2B ). Of notable interest was the fact HCRT54-66-NH2 staining was generally restricted to distinct populations (not unlike what was observed with flu antigens) while HCRT86-97-NH2 staining was more tail-like, suggesting large amounts of low affinity tetramer cross-reactivity ( Figure 2D ).
This data was later As expected, we found strong significant bias in TCRα/β usage (mostly for TRAV and TRBV segments) specific of each epitope, except for HCRT54-66-NH2 and HCRT86-97-NH2
where large amount of sequence sharing was found across the two highly homologous HCRT epitope and sequence usage diversity was higher in comparison to flu epitopes To explore differential CDR3 in control versus narcolepsy with these epitopes we also Table 4 ). Strikingly, we found that pHA273-287 and NP17-31 tetramer sequences, in many cases sharing both TCR and  chains were present in these cultures, most notably in the cultures than had been blocked by anti DR and DP
antibodies. Interestingly, we also found a significant number of sequences shared with HCRT54-66-NH2, HCRT86-97-NH2 tetramer sequences suggesting mimicry with one or several unknown peptide variants in Pandemrix ® . As a control, no sharing was found with single sorted CD8 + cell TCR sequences reactive to Pandemrix ® were isolated using a similar procedure (data not shown).
Shared CD3 analysis across subjects per tetramer indicate extensive sharing of J24 CDR3CAVETDSWGKLQF
We next analyzed sharing of CDR3CDR3and CDR3pairs across patients and diagnosis ( Figure 3 ). Not surprisingly, sharing of CDR3 was more frequent than sharing of CDR3and exact CDR3 pairs were very rarely shared across subjects.
Sharing for viral epitope pHA273-287 and NP17-31 tetramers was as expected from strong usage preference reported in Supplementary Figure 3 (for example TRAJ23 for pHA273-287 CDR3 CATDAYNTDKLIF). The most striking finding was extensive sharing of J24 CDR3 CAVETDSWGKLQF in 3 and 2 patients with HCRT86-97-NH2 and HCRT54-66-NH2
respectively as well as in 4 controls with HCRT86-97-NH2 and HCRT54-66-NH2 ( Figure 3G and J). As J24 is a low usage segment (0.8%), this is highly significant. Of notable importance was the fact these J24 CDR3 did not share CDR3 (see supplementary   Table 5 ) except for 2 patients (26 occurrences) sharing CDR3 CAVETDSWGKLQF:
CDR3 CATSSGGGGKAYGYTF (Figure 3 ). This suggests that TCR is less important for interaction of these TCRwith HCRT86-97-NH2 and HCRT54-66-NH2 when presented by DQ0602. In addition, we found that a specific CDR3 CASSQERGSYNEQFF using V4-2 was the second top CDR3 recognizing NP17-31 across subjects, with positivity in 4 patients (48 occurrences) but no controls. Sharing of V4-2 containing CRD3
CASSQETQGRNYGYTF (labelled in red) was also seen in pHA273-287 and HCRT86-97-NH2 associated tetramers. These did not share similar CRD3however (see supplementary   Table 6 ). For pairing and details of all TRAJ24 and TRVB4-2 positive clones obtained with various tetramers see below.
Shared CDR3 analysis across tetramers does not reveal evident mimicry between tested flu epitopes and HCRT86-97-NH2 and HCRT54-66-NH2
As mentioned above, pHA273-287 and HCRT54-66-NH2/ HCRT86-97-NH2 have been suggested to share epitope homology 18, 24 , a result confirmed using http://tools.iedb.org/cluster/reference/ 45 , with three EVB sequences as anchor ( Figure   3E ). Based on this finding, mimicry was proposed but not demonstrated 18, 24 . To search for mimicry across pHA273-287, NP17-31, HCRT54-66-NH2 and HCRT86-97-NH2, we first analyzed sharing of CDR3CDR3and CDR3pairs across epitopes.
Supplementary Table 7 shows cross tabulations of shared sequences across epitopes.
A large number of sequences were shared between HCRT54-66-NH2 and HCRT86-97-NH2 tetramers across CDR3 (6%), CDR3, (10%) and both CDR3 (3.4%), a result that is not surprising considering that HCRT54-66-NH2 and HCRT86-97-NH2 only differ in their Namidated C-terminal end, L-NH2 (hypocretin-1) and M-NH2 (hypocretin-2) in P9 of the binding repertoire (Supplementary Table 7 ). In contrast, pHA273-287, a viral epitope which has been suggested to be a mimic of HCRT and has some homology with HCRT54-66-NH2
and HCRT86-97-NH2 (see Figure 3E ) shared very few of the same clones with HCRT54-66-NH2 and HCRT86-97-NH2, for example only 6% for CDR3, 1.6 % for CDR3 (sharing at that level could be just above random) and none and 2 for both CDR3 for HCRT54-66-NH2 and HCRT86-97-NH2 respectively. Potential sharing was even lower with NP17-31, which shared a few clones with pHA273-287, but at even lower level with HCRT86-97-NH2
and HCRT54-66-NH2. Overall, the result suggests that the more distant the homology (as illustrated in Figure 3E ), the less sharing occurred, and this can only be tested formally with full CDR3 heterodimers as there is background sharing by chance of CDR3
and, more occasionally, CDR3. As some of the cross-reactivity could involve only CDR3 (our main HCRTNH2 clone is CDR3 specific and has variable CDR3) or only, CDR3 these experiments did not allow us to conclude clearly whether or not pHA273-287
or NP17-31 could act as mimics.
TRAJ24, TRAJ28 and TRBV 4-2 specific analysis
As mentioned above, TRAJ24, TRAJ28 and TRBV 4-2 are of special interest as QTL locations modulating usage of these segments. For these reasons, we explored whether single cell sequencing directed against these particular segments showed deviation in T1N versus controls. While TRAJ28 did not show any particular over representation in our data, we observed extensive usage of TRAJ24 and TRBV4.2. Supplementary Table   5 reports on all TRAJ24 positive clones found in all cultures. We focused on clones containing J24 CDR3 CAVETDSWGKLQF the major CDR3shared across patients and controls following HCRTNH2 stimulation ( Figure 3 ). All these clones also use TRAV2. As can be seen, this CDR3generally occurs in the context of diverse CDR3scontaining TRBV15, TRBV2, TRBV29-1, TRBV9 in controls and TRBV15, TRBV3-1, TRBV7-2 and TRBV20-1 in patients with only TRAV15-CATSSGGGGKAYGYTF CDR3shared by 2 patients and one control following HCRTNH2 culture and tetramer isolation. Of note, CAVETDSWGKFQF was not observed in any subject, control or T1N. Supplementary Table 6 reports on all TRBV4-2 positive clones found in all cultures. One potentially interesting finding is the frequent CDR3CASSQERGAYNEQFF in association with TRAV12-2 in 4 patients (with TRAJ22 in 3) and no controls after NP17-31 stimulation.
Discussion
In this work, we screened two potential autoantigens for DQ0602 binding and T cell reactivity using tetramer staining of PBMCs of T1N and control cases. We found limited TCR reactivity directed toward any segment of the native HCRT sequence, but strong Relevant to T1N, we also found that patients have higher numbers of CD4 + T cells binding HCRT54-66-NH2 when presented by DQ0602, the major HLA allele associated with T1N (97% versus 25% in controls). Recent onset cases also showed significantly higher numbers of T cells recognizing HCRT86-97-NH2, a peptide differing from only one aminoacid with HCRT86-97-NH2. These results indicate that autoreactivity to amidated HCRTNH2 fragments is common in both patients and controls but occurs at significantly higher levels in patients. These findings are consistent with other publications reporting crossreactivity to HCRT in both cases and controls 19, 20 .
The findings above could reflect causality, cross-reactivity secondary to hypocretin cell loss via another mechanism, or an epiphenomenon. Strikingly however, the top We also demonstrate that T1N is associated with differential reactivity to at least two flu peptides derived from X-179A, the reassortant strain used in Pandemrix ® . This vaccine has been significantly associated with T1N onset in Northern Europe 34 , although risk varies across countries 34 Similarly, the diversity of flu epitopes involved may explain differential risk after Pandemrix ® vaccination, as it has been suggested vaccination coincidentally with the H1N12009 pandemic was a possible factor explaining why this vaccine in Northern Europe, and not administration of a very similar adjuvanted vaccine to Pandemrix ® , Arepanrix ® , in Canada was not strongly associated with T1N 47 . Our result is a first step in attempting to unravel this complexity. More extensive tetramer sequencing studies using bar coded tetramers will be needed to fully understand the spectrum of cross reactivity of flu and hypocretin autoreactive T cells involved in T1N.
Methods
Ethics Statement
This study was reviewed and approved by the Stanford University Institutional Review Board (Protocol # 14325, Registration # 5136). Informed consent was obtained from each participant.
Participants
All patients with narcolepsy (n = 32; 44% male; mean age ± SEM, 18.9 ± 1.7 years; range, 6 to 53 years) had cataplexy with an onset age of 15.6 ± 1.6 years (ranging from Table 1) were synthesized with >90% purity at GenScript NJ and dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 5 mM or 10 mM as applicable. overnight at 4°C by end-to-end rotation. Agarose beads were washed with 1.5 ml of 50 mM Tris-HCl (pH=8.0), 100 mM NaCl and 10 mM imidazole. Proteins were eluted with elution buffer (50 mM Tris-HCl (pH=8.0), 100 mM NaCl and 300 mM imidazole) and analyzed by coomassie blue (Cat# 161-0803, Bio-Rad) (Fig S4A) . 
Constructs of DQ0602 and HLA-DM
Purification of monomer DQ0602
L of
Biotinylation in vitro
Biotinylation of DQ0602 was conducted in vitro using BirA standard reaction kit (Cat# BirA500, Avidity) according to the manufacturer's instructions. Firstly, buffer was exchanged to 50 mM bicine (pH=8.1). Then, 312.16 μl of purified DQ0602 (4.485 mg/ml; molecular weight: 70.4 kDa) was incubated with 50 μl of BiomixA, 50 μl of BiomixB, 5 μl of BirA (1 mg/ml), and 82.84 μl of 50 mM bicine (pH=8.1) overnight at 30°C. Free biotin was decreased and buffer was exchanged back to PBS using a 10K centrifugal filter. One aliquot was incubated with streptavidin (Cat# 1244-360, PerkinElmer) and biotinylation quality was determined by coomassie blue. Sample was then run on FPLC and fractions were tested with a NuPAGE ® Bis-Tris gel. Fractions 23-26 were combined and adjusted to 2 mg/ml with PBS for peptide exchange and tetramer staining.
Peptide exchange
Cleavage was conducted by incubation of 250 μl of 2 mg/ml biotinylated DQ0602 (Bio- 
Tetramer generation
The neutralized reaction (above) was incubated with PE-streptavidin (Cat# 405204, BioLegend) at 6:1 molar ratio of Bio-DQ0602:PE-streptavidin (1 μg of Bio-DQ0602:0.62 μl of PE-streptavidin) for 1 hour at RT in dark. 10 μl of streptavidin agarose slurry (Cat# N-1000-005, Solulink) (for every 5 μg of Bio-DQ0602) was spun down at 8,000rpm for 3 minutes, washed once with 1 ml of PBS, and incubated with the mixture for 30 minutes at RT (mixing well for every 10 minutes). Beads were spun down at 12,000rpm for 5 minutes. Supernatant was transferred to a centrifugal filter unit (REF# UFC30GV00, EMD Millipore) and centrifuged at 12,000rpm for 2 minutes. Tetramer DQ0602 was concentrated in PBS (pH=7.4) by centrifugation at 13,000rpm for 5 minutes using an 100 kDa centrifugal unit (REF#, UFC510096, EMD Millipore) for 3 times.
Pandemrix Cell culture and tetramer sorting
Tetramer staining was previously described 48, 49 . Briefly, PBMCs were stimulated with100 ng/ml (final concentration of HA) Pandemrix ® in a 50 ml culture flask (2. 
Single cell TCR sequencing
Single cell paired TCR sequencing was performed as described in Han et al. 51 . DNA of around 350 to 380 bp was purified using a QIAquick ® gel extraction kit (Cat# 28706, Qiagen) and then sequenced on MiSeq platform for a pair-ended 2x250 run.
Fastq files were analyzed with a customized TCRseq pipeline at The Human Immune
Monitoring Center (HIMC) at Stanford.
TCR Bulk sequencing
PBMCs were used to separate the CD4 + memory cells (Memory CD4+T cell isolation kit, cat. 130-091-893. Milteny Biotec). TCR alpha and beta repertoires were amplified from total RNA by ARM-PCR procedure 52 and sequenced by 2x101 HiSeq 2000 and 2x151
HiSeq 4000 at the Stanford Genome Sequencing Service Center. Data analysis was as follows. Briefly, the quality of raw FASTQ files was assessed using FASTQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Post quality control, FLASH was used to merge the paired end reads 53 . BLAST databases were constructed from IMGT TCR α/β sequences using local blast binaries 54 . The fastq file was converted into fasta and simultaneously processed into equal chunks of fasta records which were then processed using custom python-based analysis pipeline implemented on the Stanford University Genomics Cluster. Briefly each fasta chunk was used to query the BLAST database and Identify the TCR C, J & V Regions. The CDR3s were then extracted and their frequency along with usage of V, J families computed.
Statistical analyses
Statistical comparisons were performed using two-tailed Mann-Whitney U tests, paired
Wilcoxon non parametric tests or Fisher's exact tests whenever most appropriate. Data were plotted using GraphPad PRISM 5. P-value <0.05 were considered statistically significant. All data wrangling and handling was implemented with custom python scripts. R function mantelhaen.test was used to perform Mantel-Haenszel chi-squared test to assess enrichment of TCR families comparing bulk sequencing to single cell sequencing. In most cases, these CRD3 CDR3(see supplementary Table   7 ). We also found sharing of TRBV4.2 containing CRD3
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(labeled in red) in patients with NP17-31 only and sharing of TRBV4.2 containing CRD3 led in red) in pHA273-287 and HCRT86-97-NH2 associated tetramers although these do not share a similar CRD3
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